Oncolytics Biotech Files 6-K, Attaches Press Release
Ticker: ONCY · Form: 6-K · Filed: Jan 4, 2024 · CIK: 1129928
| Field | Detail |
|---|---|
| Company | Oncolytics Biotech INC (ONCY) |
| Form Type | 6-K |
| Filed Date | Jan 4, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulatory-filing, press-release, foreign-issuer
TL;DR
**Oncolytics Biotech just filed a 6-K with a press release, so check for new company news!**
AI Summary
Oncolytics Biotech Inc. filed a 6-K on January 4, 2024, indicating it is a foreign private issuer submitting a report for the month of January 2024. This filing primarily serves to attach a press release as Exhibit 99.1, which is a common way for foreign companies to disclose information to U.S. investors. For stockholders, this means the company is providing an update, likely about a material event, which could impact the stock's future performance depending on the content of the attached press release.
Why It Matters
This filing signals that Oncolytics Biotech Inc. has new information to share, likely through the attached press release, which could contain important updates about their drug development, clinical trials, or financial performance, directly influencing investor sentiment and stock value.
Risk Assessment
Risk Level: low — The filing itself is routine for a foreign private issuer and doesn't inherently present a risk, but the content of the attached press release could introduce risks or opportunities.
Analyst Insight
Investors should immediately review the attached Exhibit 99.1 (Press Release) to understand the specific news or updates Oncolytics Biotech Inc. is disclosing, as this will contain the material information that could affect the stock price.
Key Players & Entities
- Oncolytics Biotech Inc. (company) — the registrant filing the 6-K
- January 2024 (date) — the month for which the report is filed
- 001-38512 (other) — Commission File Number for Oncolytics Biotech Inc.
- Exhibit 99.1 (other) — the attached press release
FAQ
What is the primary purpose of this 6-K filing by Oncolytics Biotech Inc.?
The primary purpose of this 6-K filing is to submit a report for the month of January 2024 and to furnish a Press Release, which is listed as Exhibit 99.1.
Is Oncolytics Biotech Inc. considered a domestic or foreign issuer based on this filing?
Based on the filing, Oncolytics Biotech Inc. is a 'Foreign Private Issuer' as indicated by its use of Form 6-K and the address in Calgary, Alberta, Canada.
What is the Commission File Number for Oncolytics Biotech Inc. as stated in this filing?
The Commission File Number for Oncolytics Biotech Inc. is 001-38512.
Where are the principal executive offices of Oncolytics Biotech Inc. located?
The principal executive offices of Oncolytics Biotech Inc. are located at Suite 804, 322 11th Avenue SW, Calgary, Alberta, Canada T2R 0C5.
What type of annual report form does Oncolytics Biotech Inc. file?
Oncolytics Biotech Inc. indicates by check mark that it files annual reports under cover Form 20-F.
Filing Stats: 334 words · 1 min read · ~1 pages · Grade level 17.1 · Accepted 2024-01-04 13:01:14
Filing Documents
- form6kupdateletter.htm (6-K) — 18KB
- oncyupdateletter.htm (EX-99.1) — 32KB
- 0001129928-24-000002.txt ( ) — 51KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Oncolytics Biotech Inc. (Registrant) By s Kirk Look Date January 4, 2024 Kirk Look Chief Financial Officer